Japan Pharmas Fight Off Foreign Inroads In Local Generics Market
This article was originally published in PharmAsia News
Japanese drug makers are using mergers and the new generics market created by the government to counter the flood of foreign drug makers into that same market
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.